← All trials
NCT05476497
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2022
- Primary completion
- Oct 31, 2024
- Completion date
- Oct 31, 2024
- First posted
- Jul 27, 2022
- Last posted
- Oct 12, 2022
- Enrollment
- 58
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Allergy TherapeuticsLead sponsor
- Allergy TherapeuticsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.